Pep IQ
← Pep IQ
Substantial. KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH) — the anti-inflammatory tail without the melanocortin-receptor-binding pigmentation domain. Mechanism: direct inhibition of NF-κB and MAP-kinase inflammatory signalling, reducing TNF-α, IL-1β, and IL-6 cytokine secretion at nanomolar concentrations. The Brzoska et al. 2008 review (Annals of the Rheumatic Diseases) established α-MSH peptides as a class of anti-inflammatory agents. Dalmasso et al. 2008 (Gastroenterology) demonstrated PepT1-mediated tripeptide uptake in intestinal epithelial cells — orally delivered KPV reduced DSS- and TNBS-induced colitis severity in mice via PepT1 (not melanocortin receptor) mechanism, validating the oral route biologically.
Two distinct routes by target. Oral (preferred for gut inflammation): 200–500 mcg, 1–2× daily on empty stomach 30 minutes before food — empty-stomach dosing reduces competition with dietary peptides for PepT1 transport. SubQ (preferred for systemic inflammation): 100–500 mcg daily. Topical: 0.01–0.1% solutions or creams for skin inflammation. Cycle 5 days on, 2 days off, in 8-week courses. KPV does not bind melanocortin receptors (the C-terminal fragment lacks the His-Phe-Arg-Trp core sequence at positions 6–9 that binds those receptors), so unlike melanotan compounds, KPV does not cause pigmentation, sexual stimulation, or facial flushing.
No large-scale human RCTs of KPV have been published. The strong preclinical evidence — particularly the gut-inflammation work — has not yet translated into Phase 2/3 human trials. Some small pilot work and case reports in inflammatory bowel disease, but the substantial anti-inflammatory claim rests primarily on cell-line and animal data plus the established α-MSH parent-peptide research base.
Not FDA-approved. Sold as a research peptide. Generally well-tolerated based on rodent safety data and limited human community use — no significant toxicity signals at therapeutic doses. The primary safety caveat is the absence of large human safety trials. Theoretical melanoma caution is sometimes raised because KPV is α-MSH-derived, but the lack of melanocortin receptor binding makes this a weaker concern than for melanotan compounds.
KPV is one of the cleaner peptides on the platform — a small, well-characterised tripeptide with a specific mechanism (NF-κB inhibition), genuine oral bioactivity (PepT1 transport), and a favourable preclinical safety profile. Standard protocol: 200–500 mcg orally for gut, SubQ for systemic, 5-on/2-off cycled in 8-week courses. Pep IQ flags this honestly: the preclinical data is solid, particularly in colitis models, but human RCTs have not been done at scale. Useful for inflammatory gut conditions if you accept the evidence framework; not a compound where outcomes can be promised. Pairs well with BPC-157 (different mechanism — repair vs anti-inflammatory) for combined gut protocols.
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH) — the three final amino acids (Lysine-Proline-Valine) of a 13-amino-acid hormone involved in skin pigmentation, immune regulation, and inflammation control. Researchers discovered that this tiny fragment retains α-MSH's anti-inflammatory activity while lacking its broader systemic hormonal effects — including the melanin production and appetite/sexual function modulation associated with the full hormone.
The key insight came from two separate directions: first, that KPV could inhibit NF-κB activation at nanomolar concentrations — suggesting genuinely potent anti-inflammatory activity from an extremely small molecule; second, that KPV is actively transported into cells by PepT1, a di/tripeptide transporter expressed in the small intestine and upregulated in inflamed colonic tissue during IBD.
This second finding is mechanistically elegant: KPV works best in inflamed gut tissue because that tissue actively transports it. The sicker the gut, the better it absorbs KPV. This is the kind of context-responsive mechanism that makes KPV a genuinely interesting compound rather than a simple anti-inflammatory.
The PepT1 advantage: Most peptides cannot be taken orally — they are degraded in the gut before absorption. KPV is an exception because PepT1 actively transports it intact into intestinal epithelial and immune cells. This allows oral administration to produce meaningful concentrations in colonic tissue — exactly where IBD inflammation occurs. Furthermore, PepT1 is upregulated in IBD-inflamed colon, creating a self-targeting mechanism: inflamed tissue absorbs more KPV than healthy tissue.
KPV's anti-inflammatory mechanism operates through two converging pathways, both independently validated, plus a delivery mechanism that makes it unusually practical for gut applications compared to most peptides.